ID: ALA4288259

Max Phase: Preclinical

Molecular Formula: C26H26ClF3N2O3

Molecular Weight: 506.95

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)c1ccc(N2CC3(CCN(Cc4cc(C(F)(F)F)c(Cl)cc4C4CC4)CC3)CC2=O)cc1

Standard InChI:  InChI=1S/C26H26ClF3N2O3/c27-22-12-20(16-1-2-16)18(11-21(22)26(28,29)30)14-31-9-7-25(8-10-31)13-23(33)32(15-25)19-5-3-17(4-6-19)24(34)35/h3-6,11-12,16H,1-2,7-10,13-15H2,(H,34,35)

Standard InChI Key:  ZWSMKWCCXXBHEW-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 506.95

Molecular Weight (Monoisotopic): 506.1584

AlogP: 5.95

#Rotatable Bonds: 5

Polar Surface Area: 60.85

Molecular Species: ACID

HBA: 3

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 4.12

CX Basic pKa: 7.59

CX LogP: 2.27

CX LogD: 2.10

Aromatic Rings: 2

Heavy Atoms: 35

QED Weighted: 0.54

Np Likeness Score: -0.71

References

1. Liu W, Hussain Z, Zang Y, Sweis RF, Romero FA, Finke PE, Moningka R, Bao J, Plotkin MA, Shang J, Dingley KH, Salituro G, Murphy BA, Howard AD, Ujjainwalla F, Wood HB, Duffy JL..  (2018)  Optimization of Preclinical Metabolism for Somatostatin Receptor Subtype 5-Selective Antagonists.,  9  (11): [PMID:30429950] [10.1021/acsmedchemlett.8b00306]

Source

Source(1):

• Scientific Literature